MiNK Therapeutics, Inc. (INKT)
Market Cap | 58.67M |
Revenue (ttm) | n/a |
Net Income (ttm) | -9.74M |
Shares Out | 3.99M |
EPS (ttm) | -2.50 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 83,603 |
Open | 16.05 |
Previous Close | 15.16 |
Day's Range | 14.36 - 16.05 |
52-Week Range | 4.56 - 76.00 |
Beta | 0.41 |
Analysts | Hold |
Price Target | 37.50 (+154.76%) |
Earnings Date | Aug 14, 2025 |
About INKT
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients wi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INKT stock is "Hold." The 12-month stock price target is $37.5, which is an increase of 154.76% from the latest price.
News

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy iNKT cells uniquely remodel the tumor microenvironment, overcome immu...

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
MiNK Therapeutics, Inc. INKT stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro.

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ce...

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings Non-dilutive NIH funding supports development of MiNK's allogeneic iNK...

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Zack Armen - IR Jennifer Buell - President and CEO Christine Klaskin - Principal Fi...

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural ...

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine ...

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natura...

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers Addition of AgenT-797 with ...

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural...

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Ex...

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 0...

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) c...

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) ce...

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Execu...

MiNK Reports Second Quarter 2024 Results and Business Update
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...